Acetylsalicylic acid and dipyridamole improve the early patency of aorta-coronary bypass grafts. A double-blind, placebo-controlled, randomized trial

J Thorac Cardiovasc Surg. 1985 Sep;90(3):373-7.


A total of 125 patients undergoing aorta-coronary bypass grafting for disabling angina were randomized to receive either 330 mg of acetylsalicylic acid (aspirin) plus 75 mg of dipyridamole three times daily or a placebo for 6 months postoperatively. In addition, all patients were given warfarin for 3 months. Repeat angiography was performed at 6 months in 103 patients. In the treatment group 95 grafts were implanted in 48 patients, of which 87 were patent (91.6% patency rate). This figure compares with 88 grafts patent out of 118 implanted in 55 patients in the placebo group (74.6% patency rate) (p less than 0.01). We conclude that antiplatelet therapy improves the early patency of saphenous vein aorta-coronary bypass grafts.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aspirin / therapeutic use*
  • Clinical Trials as Topic
  • Coronary Artery Bypass*
  • Dipyridamole / therapeutic use*
  • Double-Blind Method
  • Drug Therapy, Combination
  • Graft Occlusion, Vascular / drug therapy*
  • Humans
  • Middle Aged
  • Placebos
  • Random Allocation


  • Placebos
  • Dipyridamole
  • Aspirin